Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia-Reference-Cited by-同舟云学术

Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia

Published:2018-11-19 Issue:1 Volume:7 Page:
ISSN:2162-3619
Container-title:Experimental Hematology & Oncology
language:en
Short-container-title:Exp Hematol Oncol

Author:

Jastaniah Wasil,Elimam Naglla,Abdalla Khalid,AlAzmi Aeshah A.,Elgaml Aml M.,Alkassar Ahmad,Daghistani Mustafa,Felimban Sami

Funder

King Abdullah International Medical Research Center

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s40164-018-0121-x.pdf

Reference27 articles.

1. Hunger SP, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(14):1663–9.

2. Kahn JM, Keegan THM, Tao L, Abrahao R, Bleyer A, Viny AD. Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer. 2016;122(17):2723–30.

3. Schultz KR, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the pediatric oncology group (POG) and children’s cancer group (CCG). Blood. 2007;109:926–35.

4. Borowitz MJ, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a children’s oncology group study. Blood. 2008;111:5477–85.

5. Vora A, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15(8):809–18.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early response and outcomes of bone marrow to chemotherapy in T-Cell Acute Lymphoblastic Leukemia;Pakistan Journal of Medical Sciences;2024-03-18

2. Dynamics of minimal residual disease defines a novel risk-classification and the role of allo-HSCT in adult Ph-negative B-cell acute lymphoblastic leukemia;Leukemia & Lymphoma;2022-09-13

3. Unilateral Cytomegalovirus Retinitis in a Child With Acute Lymphoblastic Leukemia While on Maintenance Chemotherapy;Cureus;2021-05-26

4. T cell ALL in a child with Ataxia telangiectasia; diagnosis and management challenges;Hematology;2021-01-01

5. DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML;Cancers;2020-10-17